Literature DB >> 7850952

Opposing effects of plasma epinephrine and norepinephrine on coronary thrombosis in vivo.

H Lin1, D B Young.   

Abstract

BACKGROUND: It is well known that plasma catecholamines and myocardial infarction have a close relation and that coronary artery thrombosis is a major cause of myocardial infarction. In addition, epinephrine is known to be a prothrombogenic agent in vivo. However, the role of the other major circulating catecholamine, norepinephrine, in the development of coronary thrombosis is somewhat uncertain, although the role of norepinephrine is often considered analogous to the role of epinephrine. Therefore, the present study was designed to investigate the effect of norepinephrine and its interaction with epinephrine on coronary thrombosis. METHODS AND
RESULTS: To compare the effects of epinephrine and norepinephrine on coronary thrombosis, we analyzed the frequency of cyclic blood flow reductions (CFRs) in an anesthetized canine model of coronary thrombosis (n = 25). Three experiments were used in the present study. In the first experiment with epinephrine infusion, plasma epinephrine was elevated from 0.46 +/- 0.25 to 27.7 +/- 1.85 nmol/L. The frequency of CFRs increased by more than 60%, from 7.1 +/- 0.5 to 11.5 +/- 0.7 in 40 minutes (P < .01). The second experiment included three experimental periods: control, norepinephrine infusion, and norepinephrine infusion plus epinephrine infusion. Norepinephrine was infused to raise plasma norepinephrine from 1.3 +/- 0.2 to 32.4 +/- 4.3 nmol/L. The frequency of CFRs in the dogs was markedly reduced, from 7.89 +/- 0.42 to 2.41 +/- 1.08 in 40 minutes (P < .01), whereas arterial pressure was elevated from 88 +/- 3 to 118 +/- 5 mm Hg (P < .01). However, when epinephrine infusion was added to the norepinephrine infusion, the frequency of CFRs increased from 2.41 +/- 1.08 to 7.74 +/- 1.12 in 40 minutes (P < .01). In the third experiment, a servocontrol device was used during the norepinephrine infusion to prevent rises in coronary arterial pressure. As a result of the norepinephrine infusion, the frequency of CFRs was reduced from 7.47 +/- 0.71 to 0.83 +/- 0.65 in 40 minutes (P < .01), even though the coronary arterial pressure was not altered.
CONCLUSIONS: The present study demonstrated that infusion of epinephrine stimulated coronary artery thrombosis, whereas infusion of norepinephrine inhibited coronary artery thrombosis. In addition, the inhibitory effect of norepinephrine on coronary thrombosis is independent of increases in coronary arterial pressure. Therefore, the present findings suggest that epinephrine and norepinephrine have opposing effects on coronary thrombosis in dogs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7850952     DOI: 10.1161/01.cir.91.4.1135

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  Impact of the human circadian system, exercise, and their interaction on cardiovascular function.

Authors:  Frank A J L Scheer; Kun Hu; Heather Evoniuk; Erin E Kelly; Atul Malhotra; Michael F Hilton; Steven A Shea
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

2.  Effects of Recombinant Human Megakaryocyte Growth and Development Factor (rHuMGDF) on Platelet Production, Platelet Aggregation, and Thrombosis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

Review 3.  Management of cardiogenic shock complicating acute myocardial infarction: A review.

Authors:  Ashish H Shah; Rishi Puri; Ankur Kalra
Journal:  Clin Cardiol       Date:  2019-03-27       Impact factor: 2.882

4.  Intermittent hypoxia inhibits epinephrine-induced transcriptional changes in human aortic endothelial cells.

Authors:  Rengul Cetin-Atalay; Angelo Y Meliton; Kaitlyn A Sun; Mariel E Glass; Parker S Woods; Ying-Jie Peng; Yun Fang; Robert B Hamanaka; Nanduri R Prabhakar; Gökhan M Mutlu
Journal:  Sci Rep       Date:  2022-10-13       Impact factor: 4.996

5.  The interaction of vasoactive substances during exercise modulates platelet aggregation in hypertension and coronary artery disease.

Authors:  Konstantinos Petidis; Stella Douma; Michael Doumas; Ilias Basagiannis; Konstantinos Vogiatzis; Chrysanthos Zamboulis
Journal:  BMC Cardiovasc Disord       Date:  2008-05-27       Impact factor: 2.298

6.  Assessment and management of cardiovascular disease in the intensive care unit.

Authors:  David Jonathan Cook; Stephen Webb; Alastair Proudfoot
Journal:  Heart       Date:  2021-06-24       Impact factor: 5.994

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.